Annual EBITDA
-$118.35 M
+$32.26 M+21.42%
31 December 2023
Summary:
Adverum Biotechnologies annual earnings before interest, taxes, depreciation & amortization is currently -$118.35 million, with the most recent change of +$32.26 million (+21.42%) on 31 December 2023. During the last 3 years, it has fallen by -$4.55 million (-4.00%). ADVM annual EBITDA is now -6467.54% below its all-time high of -$1.80 million, reached on 31 December 2012.ADVM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$28.33 M
-$8.40 M-42.18%
30 September 2024
Summary:
Adverum Biotechnologies quarterly earnings before interest, taxes, depreciation & amortization is currently -$28.33 million, with the most recent change of -$8.40 million (-42.18%) on 30 September 2024. Over the past year, it has increased by +$4.69 million (+14.20%). ADVM quarterly EBITDA is now -88434.38% below its all-time high of -$32.00 thousand, reached on 31 March 2013.ADVM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$99.25 M
+$4.69 M+4.51%
30 September 2024
Summary:
Adverum Biotechnologies TTM earnings before interest, taxes, depreciation & amortization is currently -$99.25 million, with the most recent change of +$4.69 million (+4.51%) on 30 September 2024. Over the past year, it has increased by +$26.18 million (+20.87%). ADVM TTM EBITDA is now -310050.00% below its all-time high of -$32.00 thousand, reached on 31 March 2013.ADVM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADVM EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.4% | +14.2% | +20.9% |
| 3 y3 years | -4.0% | +24.6% | +30.9% |
| 5 y5 years | -65.9% | -69.5% | -55.0% |
ADVM EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -4.0% | +21.4% | -42.2% | +33.2% | at high | +34.5% |
| 5 y | 5 years | -76.7% | +21.4% | -69.5% | +34.6% | -55.0% | +34.5% |
| alltime | all time | -6467.5% | +21.4% | <-9999.0% | +34.6% | <-9999.0% | +34.5% |
Adverum Biotechnologies EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$28.33 M(+42.2%) | -$99.25 M(-4.5%) |
| June 2024 | - | -$19.93 M(-22.9%) | -$103.94 M(-10.0%) |
| Mar 2024 | - | -$25.84 M(+2.8%) | -$115.54 M(-2.4%) |
| Dec 2023 | -$118.35 M(-21.4%) | -$25.15 M(-23.8%) | -$118.35 M(-5.6%) |
| Sept 2023 | - | -$33.02 M(+4.7%) | -$125.43 M(-4.7%) |
| June 2023 | - | -$31.53 M(+10.1%) | -$131.66 M(-7.6%) |
| Mar 2023 | - | -$28.65 M(-11.1%) | -$142.55 M(-5.4%) |
| Dec 2022 | -$150.61 M(+6.5%) | -$32.23 M(-17.9%) | -$150.61 M(-0.6%) |
| Sept 2022 | - | -$39.25 M(-7.5%) | -$151.48 M(+1.1%) |
| June 2022 | - | -$42.42 M(+15.6%) | -$149.79 M(-0.6%) |
| Mar 2022 | - | -$36.71 M(+10.9%) | -$150.71 M(+6.5%) |
| Dec 2021 | -$141.48 M(+24.3%) | -$33.10 M(-11.9%) | -$141.48 M(-1.5%) |
| Sept 2021 | - | -$37.56 M(-13.3%) | -$143.68 M(+8.1%) |
| June 2021 | - | -$43.34 M(+57.7%) | -$132.94 M(+12.6%) |
| Mar 2021 | - | -$27.48 M(-22.2%) | -$118.08 M(+3.8%) |
| Dec 2020 | -$113.79 M(+69.9%) | -$35.30 M(+31.6%) | -$113.79 M(+16.4%) |
| Sept 2020 | - | -$26.82 M(-5.8%) | -$97.79 M(+11.5%) |
| June 2020 | - | -$28.48 M(+22.8%) | -$87.68 M(+17.1%) |
| Mar 2020 | - | -$23.19 M(+20.2%) | -$74.88 M(+11.8%) |
| Dec 2019 | -$66.97 M(-6.1%) | -$19.30 M(+15.5%) | -$66.97 M(+4.6%) |
| Sept 2019 | - | -$16.71 M(+6.6%) | -$64.04 M(-2.3%) |
| June 2019 | - | -$15.68 M(+2.6%) | -$65.54 M(-5.2%) |
| Mar 2019 | - | -$15.28 M(-6.7%) | -$69.13 M(-3.1%) |
| Dec 2018 | -$71.33 M | -$16.37 M(-10.1%) | -$71.33 M(+1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$18.21 M(-5.5%) | -$70.05 M(+6.3%) |
| June 2018 | - | -$19.26 M(+10.2%) | -$65.88 M(+13.3%) |
| Mar 2018 | - | -$17.49 M(+15.9%) | -$58.17 M(+2.5%) |
| Dec 2017 | -$56.75 M(+7.1%) | -$15.09 M(+7.5%) | -$56.75 M(+6.4%) |
| Sept 2017 | - | -$14.04 M(+21.5%) | -$53.36 M(+0.7%) |
| June 2017 | - | -$11.55 M(-28.1%) | -$52.98 M(-1.6%) |
| Mar 2017 | - | -$16.07 M(+37.4%) | -$53.85 M(+1.7%) |
| Dec 2016 | -$52.97 M(+19.2%) | -$11.70 M(-14.3%) | -$52.97 M(+0.8%) |
| Sept 2016 | - | -$13.66 M(+10.0%) | -$52.57 M(-0.6%) |
| June 2016 | - | -$12.42 M(-18.2%) | -$52.87 M(+5.3%) |
| Mar 2016 | - | -$15.19 M(+34.4%) | -$50.18 M(+12.9%) |
| Dec 2015 | -$44.44 M(+76.2%) | -$11.30 M(-19.1%) | -$44.44 M(+2.3%) |
| Sept 2015 | - | -$13.96 M(+43.4%) | -$43.45 M(+15.3%) |
| June 2015 | - | -$9.73 M(+3.1%) | -$37.70 M(+14.1%) |
| Mar 2015 | - | -$9.44 M(-8.4%) | -$33.03 M(+30.9%) |
| Dec 2014 | -$25.22 M(+387.2%) | -$10.31 M(+25.6%) | -$25.22 M(+35.7%) |
| Sept 2014 | - | -$8.21 M(+62.0%) | -$18.59 M(+66.6%) |
| June 2014 | - | -$5.07 M(+208.8%) | -$11.16 M(+64.4%) |
| Mar 2014 | - | -$1.64 M(-55.3%) | -$6.79 M(+31.1%) |
| Dec 2013 | -$5.18 M(+187.3%) | -$3.67 M(+372.1%) | -$5.18 M(+244.2%) |
| Sept 2013 | - | -$778.00 K(+12.1%) | -$1.50 M(+107.2%) |
| June 2013 | - | -$694.00 K(+2068.8%) | -$726.00 K(+2168.8%) |
| Mar 2013 | - | -$32.00 K | -$32.00 K |
| Dec 2012 | -$1.80 M | - | - |
FAQ
- What is Adverum Biotechnologies annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Adverum Biotechnologies?
- What is Adverum Biotechnologies annual EBITDA year-on-year change?
- What is Adverum Biotechnologies quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Adverum Biotechnologies?
- What is Adverum Biotechnologies quarterly EBITDA year-on-year change?
- What is Adverum Biotechnologies TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Adverum Biotechnologies?
- What is Adverum Biotechnologies TTM EBITDA year-on-year change?
What is Adverum Biotechnologies annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ADVM is -$118.35 M
What is the all time high annual EBITDA for Adverum Biotechnologies?
Adverum Biotechnologies all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.80 M
What is Adverum Biotechnologies annual EBITDA year-on-year change?
Over the past year, ADVM annual earnings before interest, taxes, depreciation & amortization has changed by +$32.26 M (+21.42%)
What is Adverum Biotechnologies quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ADVM is -$28.33 M
What is the all time high quarterly EBITDA for Adverum Biotechnologies?
Adverum Biotechnologies all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$32.00 K
What is Adverum Biotechnologies quarterly EBITDA year-on-year change?
Over the past year, ADVM quarterly earnings before interest, taxes, depreciation & amortization has changed by +$4.69 M (+14.20%)
What is Adverum Biotechnologies TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ADVM is -$99.25 M
What is the all time high TTM EBITDA for Adverum Biotechnologies?
Adverum Biotechnologies all-time high TTM earnings before interest, taxes, depreciation & amortization is -$32.00 K
What is Adverum Biotechnologies TTM EBITDA year-on-year change?
Over the past year, ADVM TTM earnings before interest, taxes, depreciation & amortization has changed by +$26.18 M (+20.87%)